Press Release: Global Regulatory Partners Launches GRP-Japan Website

Press Release

Global Regulatory Partners Launches GRP-Japan website

Global Regulatory Partners Group (GRP) is proud to announce the launch of its new GRP-Japan website, a significant step in enhancing the experience of our users in Japan. This new platform reflects GRP’s commitment to innovation, accessibility, and delivering exceptional service to our stakeholders in the pharmaceutical and medical device industries.

The GRP-Japan website provides comprehensive information tailored to the needs of local Japanese distributors, patients, and healthcare providers. Users will find detailed resources related to product information of pharmaceutical and medical device products, ensuring transparency and support for all stakeholders.

Website:

We invite everyone to explore our new website and discover how GRP is continuing our mission of 

Please visit our website

グローバルレギュラトリーパートナーズ合同会社

GRP Products:

Product information for our first marketed product in Japan will be available on the website by end of January 2025.

About Global Regulatory Partners Group:

Global Regulatory Partners (GRP) is a leading provider of regulatory affairs, clinical research, and compliance services. GRP supports pharmaceutical, biotechnology, and medical device companies worldwide, ensuring successful product development and market entry.

About Global Regulatory Partners Group

Global Regulatory Partners, Inc (GRP) is a global provider of tailored clinical development, regulatory affairs, quality and pharmacovigilance services for pharma, biotech, medical devices and cosmetic industries worldwide.

Global Regulatory Partners. Inc, has now over 500 employees, 6 affiliates in 6 countries (USA, Brazil, Mexico, Japan, China and South Korea) and more than 500 satisfied clients worldwide.

In China, GRP-China has offices in three locations, Shanghai, Beijing and Hainan, and has local teams of Regulatory Affairs, Clinical Development ,Quality and Pharmacovigilance professionals, who support the clinical development and products’ registration of many pharmaceutical and medical device companies in Hainan pilot zone and in China Mainland as well.